Latest Stories
Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales
Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close to analysts’ estimates. Its non-GAAP loss of $1.25 per share was 10.5% below analysts’ consensus estimates.
Nutanix (NASDAQ:NTNX) Misses Q3 CY2025 Revenue Estimates
Hybrid multicloud computing company Nutanix (NASDAQ:NTNX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.5% year on year to $670.6 million. Next quarter’s revenue guidance of $710 million underwhelmed, coming in 5.1% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was in line with analysts’ consensus estimates.
Mobileye (NASDAQ:MBLY) Delivers Impressive Q3 CY2025
Autonomous driving technology company Mobileye (NASDAQ:MBLY) announced better-than-expected revenue in Q3 CY2025, with sales up 3.7% year on year to $504 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.
Martin Marietta Materials (NYSE:MLM) Misses Q3 CY2025 Revenue Estimates
Construction materials supplier Martin Marietta Materials (NYSE:MLM) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 12.4% year on year to $1.85 billion. The company’s full-year revenue guidance of $6.16 billion at the midpoint came in 11.7% below analysts’ estimates. Its non-GAAP profit of $6.85 per share was 2.5% above analysts’ consensus estimates.
Motorola Solutions (NYSE:MSI) Beats Q3 CY2025 Sales Expectations
Public safety technology company Motorola Solutions (NYSE:MSI) announced better-than-expected revenue in Q3 CY2025, with sales up 7.8% year on year to $3.01 billion. Its non-GAAP profit of $4.06 per share was 5.5% above analysts’ consensus estimates.
MediaAlpha (NYSE:MAX) Posts Better-Than-Expected Sales In Q3 CY2025
Insurance customer acquisition platform MediaAlpha (NYSE:MAX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 18.3% year on year to $306.5 million. On the other hand, next quarter’s revenue guidance of $290 million was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $0.40 per share was 8.2% above analysts’ consensus estimates.
Ingredion (NYSE:INGR) Misses Q3 CY2025 Revenue Estimates
Food ingredient solutions provider Ingredion (NYSE:INGR) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 2.9% year on year to $1.82 billion. Its non-GAAP profit of $2.75 per share was 4.8% below analysts’ consensus estimates.
Howard Hughes Holdings (NYSE:HHH) Reports Strong Q3 CY2025
Real estate developer Howard Hughes Holdings (NYSE:HHH) announced better-than-expected revenue in Q3 CY2025, with sales up 19.3% year on year to $390.2 million. Its GAAP profit of $2.02 per share was 32% above analysts’ consensus estimates.
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million. The company’s full-year revenue guidance of $1.34 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $1.72 per share was 5.5% above analysts’ consensus estimates.
Garrett Motion (NASDAQ:GTX) Reports Bullish Q3 CY2025
Turbocharger technology company Garrett Motion (NYSE:GTX) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.2% year on year to $902 million. The company’s full-year revenue guidance of $3.55 billion at the midpoint came in 0.6% above analysts’ estimates. Its GAAP profit of $0.38 per share was 19.1% above analysts’ consensus estimates.